Rationale: Accurate measurement of the threshold dosage of phenobarbital that can produce drug discrimination (DD) may improve our understanding of the mechanisms and properties of such discrimination.
Objectives: This study aimed to compare three methods for determining the threshold dosage for phenobarbital (D) versus no-drug (N) DD.
Materials And Methods: Rats learned a D versus N DD in two-lever operant training chambers. A titration scheme was employed to increase or decrease dosage at the end of each 18-day block of sessions depending on whether the rat had achieved criterion accuracy during the sessions just completed. Three criterion rules were employed, all based on average percent drug lever responses during initial links of the last six D and six N sessions of a block. The criteria were: D% > 66 and N% < 33; D% > 50, and N% < 50; (D% - N%) > 33. Two squads of rats were trained, one immediately after the other.
Results: All rats discriminated drug versus no drug. In most rats, dosage decreased to low levels and then oscillated near the minimum level required to maintain criterion performance. The lowest discriminated dosage significantly differed under the three criterion rules. The squad that was trained second may have benefited by partially duplicating the lever choices of the previous squad.
Conclusions: The lowest discriminated dosage is influenced by the criterion of discriminative control that is employed and is higher than the absolute threshold at which discrimination entirely disappears. Threshold estimations closer to absolute threshold can be obtained when criteria are employed that are more permissive of errors and that allow rats to maintain lever preferences.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2782425 | PMC |
http://dx.doi.org/10.1007/s00213-008-1426-y | DOI Listing |
J Toxicol Sci
November 2024
Environmental Health Science Laboratory, Sumitomo Chemical Company, Ltd.
We propose a modified Comparative Thyroid Assay (CTA, USEPA) utilizing a smaller number of Sprague-Dawley rats (N=10/group) that assesses brain thyroid hormone (TH) concentrations and periventricular heterotopia while maintaining assay sensitivity. Our recent findings demonstrated that a prenatal test cohort of the modified CTA detected a dose-dependent decrease in maternal serum T3 (up to -26%) and T4 (up to -44%) with sodium phenobarbital (NaPB) exposure at 1000 ppm and 1500 ppm, equivalent to intakes of 60 and 84 mg/kg/day, respectively. On gestation day (GD) 20, fetuses exhibited reduced serum (-26%) and brain (-29%) TH concentrations, although these reductions were not dose dependent.
View Article and Find Full Text PDFIran J Child Neurol
September 2024
Student research committee, Urmia university of medical sciences, Urmia ,Iran.
Objectives: Seizures are changes in the electrical activity of the brain. These changes can cause significant or otherwise asymptomatic symptoms. Phenobarbital and phenytoin are known drugs for treating neonatal seizures, but little clinical experience exists using other drugs.
View Article and Find Full Text PDFEpilepsia Open
December 2024
Division of Pediatric Neurology, Department of Pediatrics, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan, Taiwan.
Eur J Pharm Biopharm
November 2024
International Pharmaceutical Federation (FIP), The Hague, Netherlands; St. Louis College of Pharmacy, University of Health Sciences and Pharmacy in St. Louis, MO, USA.
This publication is the first to report current, global, pediatric oral extemporaneous compounding practices. Complete survey responses were received from 479 participants actively involved in compounding across all the World Health Organization (WHO) regions. The survey addressed oral formulation of extemporaneous liquids, including the use of commercial or in-house vehicles, flavoring excipients, source of formulation recipes, and beyond use dates (BUDs).
View Article and Find Full Text PDFBrain
December 2024
Department of Materials Science and Engineering, Koch Institute of Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Focal epilepsy is a difficult disease to treat as two-thirds of patients will not respond to oral anti-seizure medications (ASMs) or have severe off-target effects that lead to drug discontinuation. Current non-pharmaceutical treatment methods (resection or ablation) are underutilized due to the associated morbidities, invasive nature and inaccessibility of seizure foci. Less invasive non-ablative modalities may potentially offer an alternative.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!